siFAlin-TATE (R&D), 150nmol
Labelling of radiopharmaceuticals that comprise of such a SiFA group can be produced with isotopic exchange at room temperature.
siFAlin-TATE (R&D)
General Information
Product/Article No: 50139
Product name: SiFAlin-TATE
Sequence: SiFAlin-Aoa-Asn(AcNH-β-Glc)-Asp2-PEG-Tyr³-octreotate
Molecular Weight: 2161.9 g/mol (av.)
Molecular Formula: C98H141N18O30S2SiF
Product description
Labelling of radiopharmaceuticals that comprise of such a SiFA group can be produced with isotopic exchange at room temperature.
For use by qualified personnel only.
For research use only.
Quantity
Product No. 50139: 150nmol, TFA-salt
Packaging
2 mL ISO clear type I tubular glass vials (2R borosilicate clear glass vials type I);
13mm crimp neck;
Lyophilisation stoppers;
Flip-off seal.
Storage and Stability
Storage at – 20°C (± 5 °C) sealed storage, away from moisture and protected from light.
Certificates
Certificate of Quality.
Literature
Gower-Fry, L. et al. (2021) Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) 18F-Radiopharmaceuticals, Pharmaceuticals 2021, 14, 701
Lindner S. et al. (2020) Automated production of [18F]SiTATE on a Scintomics GRP™ platform for PET/CT imaging of neuroendocrine tumors, Nuclear Medicine and Biology, 2020, 88–89 (2020) 86–95
Lindner S. et al. (2020) Radiosynthesis of [18F]SiFAlin-TATE for clinical neuroendocrine tumor positron emission tomography, Nature protocols, 2020, https://doi.org/10.1038/s41596-020-00407-y
Ilhan H. et al. (2019) Biodistribution and first clinical results of 18F-SiFAlin-TATE PET a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors, Eur. J. Nucl. Med. Mol. Imaging, 2019, 47, 870–880 (2020)
